Andrea Lania
Andrea Lania is an expert in Endocrinology at IRCCS Humanitas Research Hospital (Italy). As of October 2026, ScienceLeadR ranks Andrea Lania in the top 1% of experts worldwide for Adenoma. Andrea Lania has authored 440 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 5 of them ongoing. SLR score: 1,235 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Oncology - Pharmacy - Neurology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 440
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Multicentre Clinical Validation of the THYT1 Test for Predicting Distant Metastases in Papillary Thyroid Carcinoma. PMID 42905357 — thyroid cancer, papillary, thyroid gland, neoplasm metastasis | Endocr Pathol | 2026 | 0 |
| Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue. PMID 42714696 — lung, incidence, hormones, neoplasm metastasis, nuclear medicine, neuroendocrine tumors, diagnosis, therapeutics, carcinoid tumor, endocrine system diseases | Endocrine | 2026 | 0 |
| Caspase-8 as a Candidate Mediator Associated with Everolimus Resistance in Neuroendocrine Tumors. PMID 42615220 — cells, genes, caspase 8, lung, neoplasms, caspases, hormones, everolimus, neuroendocrine tumors, therapeutics | J Mol Endocrinol | 2026 | 0 |
| Beyond weight: a stigma-free, integrated approach to obesity in patients affected by cancer. PMID 42611363 — neoplasms, obesity, therapeutics | Rev Endocr Metab Disord | 2026 | 0 |
| Partial Lipodystrophy Mimicking Cushing's Syndrome: Clinical and Metabolic Insights from a Multicenter Study. PMID 42554580 — diabetes mellitus, muscular atrophy, muscles, atrophy, leptin, lipodystrophy, hypertriglyceridemia, osteoporosis, adipose tissue, cushing syndrome | J Clin Endocrinol Metab | 2026 | 0 |
Clinical Studies 10
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Evaluate Atumelnant in Adults with Congenital Adrenal Hyperplasia 2024-519579-24-00 — safety, adrenal hyperplasia, congenital, hyperplasia | Phase 3 | Not yet recruiting | 2026 |
| A Long Term Extension Study of IMVT 1402 in Adult Patients With Graves Disease 2025-524001-33-00 — safety, graves disease | Phase 2 | Recruiting | 2026 |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen 2024-519875-24-00 — safety, neoplasms, neuroendocrine tumors, carcinoid tumor | Phase 3 | Not yet recruiting | 2025 |
| Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma NCT06645951 — pharmaceutical preparations, data collection, neoplasms, parathyroid neoplasms, pathology, adenoma, therapeutics, genetic diseases, inborn, parathyroid glands, carcinoma, male | N/A | Recruiting | 2024 |
| Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism NCT06645899 — endocrinology, hypoparathyroidism, incidence, data collection, pathology, pseudohypoparathyroidism, prevalence, pseudopseudohypoparathyroidism, therapeutics, male, bone and bones | N/A | Recruiting | 2024 |
LeadR Networks
Main global connection map